- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04655690
A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus
December 30, 2022 updated by: Novo Nordisk A/S
A Trial Investigation the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0471-0119 in Subjects With Type 1 Diabetes Mellitus
This study is looking at the safety of the new medicine, insulin NNC0471-0119, its concentrations in the blood and effect on blood sugar for the treatment of type 1 diabetes.
Insulin NNC0471-0119 will be compared to faster aspart.
The purpose of this study is to test how insulin NNC0471-0119 is tolerated by participants body, how it is transported in participants bloodstream, how long it stays there and how the blood sugar is lowered compared to faster aspart.
Participants will get either the new insulin NNC0471-0119 or faster aspart-which treatment participants get is decided by chance.
It is the first time insulin NNC0471-0119 is tested in people.
Faster aspart is a globally used medication for treatment of diabetes mellitus.
Participants will get one single injection in a fasting state which will take place at the study site.
The medicine will be injected under the skin in the stomach.
The study will last for about 13-53 days, depending on individual visit schedule.
Participants will have four clinic visits with the study doctor, one of which will require an in-house visit period of 3 days.
During the in-house visit, two intravenous cannulas will be inserted for sampling of blood and infusion of insulin.
Participants cannot be in the study if the study doctor thinks that there are risks to their health.
Women: Women cannot take part if they are of childbearing potential.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Graz, Austria, 8010
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male subject or female subject of non-childbearing potential. Non-childbearing potential being defined as surgically sterilised (i.e. documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or being postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to the day of screening.
- Aged 18-55 years (both inclusive) at the time of signing informed consent.
- Diagnosed with Type 1 Diabetes Mellitus (T1DM) greater than or equal to 1 year prior to the day of screening.
- Current total daily bolus insulin treatment less than 0.7(I)U/kg/day.
Exclusion Criteria:
- Known or suspected hypersensitivity to investigational medicinal products (IMPs) or related products.
- Participation in any clinical trial of an approved or non-approved IMP within 90 days before screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NNC0471-0119
Participants randomised to NNC0471-0119
|
Participants will be randomised to either of five dose levels 0.3, 0.6, 1.2, 2.4 or 3.6 of NNC0471-0119 nanomol per kilogram body weight, which will be administered as a single dose.
NNC0471-0119 will be administered subcutaneously (s.c., under the skin) in fasting state.
|
Active Comparator: Faster aspart
Participants randomised to faster aspart.
|
Participants will get a fixed dose of 0.2 units of fast-acting insulin aspart (Fiasp®) per kilogram body weight, administered subcutaneously (s.c., under the skin) in fasting state.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events (AEs)
Time Frame: From investigational medicinal product (IMP) administration at day 1 (Visit 2) and up to 22 days post IMP administration (Visit 3)
|
Number of events
|
From investigational medicinal product (IMP) administration at day 1 (Visit 2) and up to 22 days post IMP administration (Visit 3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of hypoglycaemic episodes
Time Frame: 0 to 24 hours after IMP administration
|
Number of episodes
|
0 to 24 hours after IMP administration
|
AUCNNC0471-0119,0-30 min/AUCNNC0471-0119,0-t: Ratio of the area under the serum NNC0471-0119 concentration-time curve from 0-30 min and 0-t, where t is the last observed time point with insulin concentration above lower limit of quantification (LLOQ).
Time Frame: 0 to 12 hours after IMP administration
|
% (Percent)
|
0 to 12 hours after IMP administration
|
AUCNNC0471-0119,2h-t/AUCNNC0471-0119,0-t: Ratio of the area under the serum NNC0471-0119 concentration-time curve from 2 hours to t and 0 to t, where t is the last observed time point with insulin concentration above LLOQ.
Time Frame: 0 to 12 hours after IMP administration
|
0 to 12 hours after IMP administration
|
|
AUCNNC0471-0119, 0-t: Area under the serum NNC0471-0119 concentration-time curve from 0 to t, where t is the last observed time point with insulin concentration above LLOQ.
Time Frame: 0 to 12 hours after IMP administration
|
h*pmol/L
|
0 to 12 hours after IMP administration
|
Cmax,NNC0471-0119: Maximum observed serum NNC0471- 0119 concentration
Time Frame: 0 to 12 hours after IMP administration
|
pmol/L
|
0 to 12 hours after IMP administration
|
tmax,NNC0471-0119: Time to maximum observed serum NNC0471-0119 concentration
Time Frame: 0 to 12 hours after IMP administration
|
Minutes
|
0 to 12 hours after IMP administration
|
t½, NNC0471-0119: Terminal half-life for NNC0471-0119
Time Frame: 0 to 12 hours after IMP administration
|
Minutes
|
0 to 12 hours after IMP administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2020
Primary Completion (Actual)
November 26, 2021
Study Completion (Actual)
November 26, 2021
Study Registration Dates
First Submitted
October 28, 2020
First Submitted That Met QC Criteria
November 30, 2020
First Posted (Actual)
December 7, 2020
Study Record Updates
Last Update Posted (Estimate)
January 2, 2023
Last Update Submitted That Met QC Criteria
December 30, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN1471-4612
- U1111-1247-7440 (Other Identifier: World Health Organization (WHO))
- 2020-000665-16 (Registry Identifier: European Medicines Agency (EudraCT))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on NNC0471-0119
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 1Austria